RecruitingPhase 2NCT07047690

A Study of Nemolizumab for the Treatment of Adults With Systemic Sclerosis

A 52-week, Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study of Nemolizumab in Adult Patients With Systemic Sclerosis

Sponsor

Galderma R&D

Enrollment

162 participants

Start Date

Feb 20, 2026

Study Type

INTERVENTIONAL

Conditions

Systemic Sclerosis

Summary

The main purpose of the study is to investigate the efficacy on cutaneous thickness and the safety of Nemolizumab in adult patients with systemic sclerosis after a 52-week treatment period and to select the optimal dose for this target population.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Nemolizumab and a drug called Placebo for people with systemic sclerosis. The study is currently recruiting participants at 3 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGNemolizumab

Subcutaneous Injection

DRUGPlacebo

Subcutaneous Injection

Locations(3)

Galderma Investigational Site # 8743

Ann Arbor, Michigan, United States

Galderma Investigational Site#7096

Arlington, Texas, United States

Galderma Investigational Site # 6213

Sankt Gallen, Switzerland

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07047690

Related Trials

A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease

NCT0708510414 locations

A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease

NCT0692554214 locations